Consensus Aligos Therapeutics, Inc.

Stocks

ALGS

US01626L2043

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 25/07/2026 +04			5-day change	1st Jan Change
4.080 ^USD	-13.01%		-28.92%	-56.22%

07-13	Aligos Therapeutics Completes Enrollment In Phase 2 B-SUPREME Study Of Pevifoscorvir Sodium For Chronic HBV Infection	CI
07-13	Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment	MT

Evolution of the Average Target: Aligos Therapeutics, Inc.

Evolution of the Target Price: Aligos Therapeutics, Inc.

Changes in Analyst Recommendations: Aligos Therapeutics, Inc.

b82c616f0c0a77b4342b5aa8f6f600._d_SVF9quxaP2YGDjy_KvZP8uGTk-Ls8tSb6OI7KUN0.h4iVZSgJgmXZjfXuwx24y9SQ0w2ulI5ThnmofdT_Y42PnpU1BQ71dNyIsQ~43ea66669d8d9430e52c1bf328f6dc93

Analysts' recommendations: Aligos Therapeutics, Inc.

05-28	Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target	MT
01-07	UBS Initiates Aligos Therapeutics at Buy With $20 Price Target	MT
19/08/24	HC Wainwright Initiates Aligos Therapeutics at Buy With $75 Price Target	MT
17/01/23	Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating	MT
06/01/23	Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2	MT
06/01/23	Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50	MT
03/11/22	SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating	MT
08/08/22	Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11	MT
05/05/22	SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7	MT
23/03/22	Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating	MT
23/03/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating	MT
23/03/22	Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15	MT
11/03/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating	MT
16/02/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating	MT
08/01/22	Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20	MT
07/01/22	SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating	MT
07/01/22	JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30	MT
09/09/21	ALIGOS THERAPEUTICS : SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target	MT
17/05/21	ALIGOS THERAPEUTICS : Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target	MT
24/03/21	ALIGOS THERAPEUTICS : Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating	MT
21/12/20	ALIGOS THERAPEUTICS : Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating	MT
10/11/20	ALIGOS THERAPEUTICS : Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target	MT
10/11/20	ALIGOS THERAPEUTICS : Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target	MT
10/11/20	ALIGOS THERAPEUTICS : JPMorgan Starts Aligos Therapeutics at Overweight With $33 Price Target	MT
10/11/20	ALIGOS THERAPEUTICS : Jefferies & Co Initiates Coverage on Aligos Therapeutics With Buy Rating, $26 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALIGOS THERAPEUTICS, INC.					+1,279.55%
	LONZA GROUP AG					+23.65%
	REVOLUTION MEDICINES, INC.					+9.39%
	BEONE MEDICINES AG					+27.54%
	IQVIA HOLDINGS INC.					+11.51%
	CELLTRION, INC.					+44.52%
	MEDPACE HOLDINGS, INC.					-5.11%
	ASCENDIS PHARMA A/S					+19.91%
	EUROFINS SCIENTIFIC SE					+8.58%
	ICON PUBLIC LIMITED COMPANY					+9.68%
	Average					+142.92%
	Weighted average by Cap.					+18.92%